The FIREFLY-2 Trial

FIREFLY-2 is a phase 3, 2-arm, randomized, multicenter, open-label study to evaluate the efficacy, safety, and tolerability of monotherapy tovorafenib, an investigational, oral, pan-RAF inhibitor versus standard of care (SoC) chemotherapy in pediatric patients with RAF-altered low-grade glioma requiring front-line systemic therapy

Sponsor: Day One Biopharmaceuticals, Inc.

Collaborator: SIOPe Brain Tumor Group LOGGIC Consortium (LOGGIC)

Status: Now enrolling patients

Condition: Low-grade glioma harboring RAF alterations

Phase: 3

NCT Number: NCT05566795

EudraCT Number: 2022-001363-27

Other Study ID Numbers: LOGGIC/FIREFLY-2

Discover more details and enrollment information about FIREFLY-2

VIEW FIREFLY-2 TRIAL

Read a plain language summary (PLS) of the clinical trial design of this study

Click to view

FIREFLY-2 Trial Sites

Trial sites are currently active in the following locations

View Trial Locations

Interested in learning more?

For clinical trial information, please email [email protected]
For medical inquiries in the US, please email [email protected]